DE60129151D1 - Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) - Google Patents

Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)

Info

Publication number
DE60129151D1
DE60129151D1 DE60129151T DE60129151T DE60129151D1 DE 60129151 D1 DE60129151 D1 DE 60129151D1 DE 60129151 T DE60129151 T DE 60129151T DE 60129151 T DE60129151 T DE 60129151T DE 60129151 D1 DE60129151 D1 DE 60129151D1
Authority
DE
Germany
Prior art keywords
callique
human
detecting
detecting egg
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129151T
Other languages
English (en)
Other versions
DE60129151T2 (de
Inventor
Eleftherios P Diamandis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mount Sinai Hospital Corp
Original Assignee
Mount Sinai Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai Hospital Corp filed Critical Mount Sinai Hospital Corp
Application granted granted Critical
Publication of DE60129151D1 publication Critical patent/DE60129151D1/de
Publication of DE60129151T2 publication Critical patent/DE60129151T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
DE60129151T 2000-10-27 2001-10-26 Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) Expired - Lifetime DE60129151T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24378900P 2000-10-27 2000-10-27
US243789P 2000-10-27
PCT/CA2001/001505 WO2002035232A2 (en) 2000-10-27 2001-10-26 Method for detecting ovarian cancer based on human kallikrein 6 (hk6)

Publications (2)

Publication Number Publication Date
DE60129151D1 true DE60129151D1 (de) 2007-08-09
DE60129151T2 DE60129151T2 (de) 2008-03-06

Family

ID=22920140

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129151T Expired - Lifetime DE60129151T2 (de) 2000-10-27 2001-10-26 Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)

Country Status (9)

Country Link
US (1) US20040096915A1 (de)
EP (1) EP1330652B1 (de)
JP (1) JP2004511810A (de)
AT (1) ATE365922T1 (de)
AU (1) AU2002213704A1 (de)
CA (1) CA2426286A1 (de)
DE (1) DE60129151T2 (de)
ES (1) ES2287169T3 (de)
WO (1) WO2002035232A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
CA2418422C (en) * 2000-08-11 2011-06-07 Mount Sinai Hospital Novel kallikrein gene
EP1332367A2 (de) * 2000-11-01 2003-08-06 Mount Sinai Hospital Nachweis von eierstockkrebs
WO2002097438A1 (en) * 2001-05-25 2002-12-05 Mount Sinai Hospital Method of detecting and monitoring prostate and ovarian cancers
KR20040081420A (ko) * 2001-10-16 2004-09-21 마운트 시나이 하스피틀 코포레이션 난소암의 검출 방법
WO2003034068A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Localization of disorders associated with kallikreins
CA2497061A1 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
US20060073525A1 (en) * 2002-08-28 2006-04-06 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
WO2004029285A2 (en) * 2002-09-26 2004-04-08 Mount Sinai Hospital Methods for detecting endocrine cancer
CA2516591A1 (en) * 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
CA2516588A1 (en) * 2003-02-27 2004-09-10 Mount Sinai Hospital Assay for detection of renal cell carcinoma
US20050106586A1 (en) * 2003-06-13 2005-05-19 Mount Sinai Hospital Detection of neurodegenerative diseases
US20060269971A1 (en) * 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
CN102989009B (zh) * 2003-12-31 2015-06-03 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
EP1718975A2 (de) * 2004-02-18 2006-11-08 Bayer HealthCare AG Diagnostika und therapeutika für mit kallikrein 6 (klk6) in zusammenhang stehende krankheiten
DE102005004294A1 (de) * 2005-01-28 2006-08-03 Bayer Healthcare Ag Auswahl und Bewertung diagnostischer Tests mittels Diskordanzanalysen-Charakteristik (DAC)
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
WO2009126455A1 (en) * 2008-04-09 2009-10-15 Smiths Detection Inc. Multi-dimensional spectral analysis for improved identification and confirmation of radioactive isotopes
US7851230B2 (en) * 2008-04-14 2010-12-14 Chang Gung Memorial Hospital Stress-induced phosphoprotein 1 as a biomarker for the detection of human ovarian cancers and endometriosis
US20140148348A1 (en) 2010-01-13 2014-05-29 Christine Kuslich Dectection of gastrointestinal disorders
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
WO2012174569A2 (en) * 2011-06-17 2012-12-20 The Board Of Trustees Of The University Of Arkansas New markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chematherapy
CN103675278A (zh) * 2013-11-19 2014-03-26 上海裕隆医学检验所股份有限公司 一种糖链抗原125定量检测试剂盒及其应用
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
KR20210111254A (ko) 2018-11-30 2021-09-10 캐리스 엠피아이, 아이엔씨. 차세대 분자 프로파일링
WO2021112918A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
IL105793A0 (en) * 1992-05-28 1993-09-22 Lilly Co Eli Protease and related dna compounds
AU4480797A (en) * 1996-09-13 1998-04-02 Dana-Farber Cancer Institute Protease m, a novel serine protease
US6268165B1 (en) * 1997-03-19 2001-07-31 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US6294344B1 (en) * 1997-03-19 2001-09-25 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
WO1998041656A1 (en) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and method for the early diagnosis of ovarian cancer
US6870027B2 (en) * 1997-03-19 2005-03-22 O'brien Timothy J. Methods for the early diagnosis of ovarian cancer
US6316213B1 (en) * 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
AU755340B2 (en) * 1998-07-02 2002-12-12 Fuso Pharmaceutical Industries, Ltd. Serine protease-specific monoclonal antibody and utilization thereof
US6942978B1 (en) * 1999-03-03 2005-09-13 The Board Of Trustees Of The University Of Arkansas Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US7935531B2 (en) * 2000-02-22 2011-05-03 Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
CA2418422C (en) * 2000-08-11 2011-06-07 Mount Sinai Hospital Novel kallikrein gene
CA2360219A1 (en) * 2000-10-27 2002-04-27 Mount Sinai Hospital Method for detecting alzheimer's disease
WO2002097438A1 (en) * 2001-05-25 2002-12-05 Mount Sinai Hospital Method of detecting and monitoring prostate and ovarian cancers
KR20040081420A (ko) * 2001-10-16 2004-09-21 마운트 시나이 하스피틀 코포레이션 난소암의 검출 방법
AU2003213960A1 (en) * 2002-04-04 2003-10-20 Mount Sinai Hospital Methods for detecting ovarian cancer
US20040015745A1 (en) * 2002-07-22 2004-01-22 Finisar Corporation Scalable socketed testing tool
CA2497061A1 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
US20060073525A1 (en) * 2002-08-28 2006-04-06 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
WO2004029285A2 (en) * 2002-09-26 2004-04-08 Mount Sinai Hospital Methods for detecting endocrine cancer
CA2516591A1 (en) * 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
CA2516588A1 (en) * 2003-02-27 2004-09-10 Mount Sinai Hospital Assay for detection of renal cell carcinoma
US20050106586A1 (en) * 2003-06-13 2005-05-19 Mount Sinai Hospital Detection of neurodegenerative diseases
US20060269971A1 (en) * 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer

Also Published As

Publication number Publication date
EP1330652A2 (de) 2003-07-30
DE60129151T2 (de) 2008-03-06
US20040096915A1 (en) 2004-05-20
ES2287169T3 (es) 2007-12-16
EP1330652B1 (de) 2007-06-27
ATE365922T1 (de) 2007-07-15
WO2002035232A2 (en) 2002-05-02
AU2002213704A1 (en) 2002-05-06
CA2426286A1 (en) 2002-05-02
JP2004511810A (ja) 2004-04-15
WO2002035232A3 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
WO2002037112A3 (en) Detection of ovarian cancer
KR101764597B1 (ko) 생물학적 샘플에서 희귀 사건 분석을 위한 고감도 다중매개변수 방법
SG169395A1 (en) Detection of cancer by elevated levels of bcl-2
DK1734368T3 (da) Annexin-autoantistoffer anvendt som markörer for lungecancer
BRPI0311233B8 (pt) métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
ATE289685T1 (de) Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
DE60033555D1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
WO2004055519A3 (en) Specific markers for pancreatic cancer
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
CA2623653A1 (en) Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis
ATE267399T1 (de) Verfahren zum nachweis von komplex-gebundenem prostata-spezifischem antigen (kpsa)
DE60025347D1 (de) Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
ATE427494T1 (de) Verfahren zur quantifizierung der akt-protein- expression
WO2007060240A3 (fr) Procede pour la mise en evidence de la presence ou de l ' absence de marquers (eef1a1 ou mark3 ) associes a la presence et/ou a la chimiosensibilite des tumeurs
WO2002004952A3 (en) Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
WO2005040806A3 (en) Use of protein asc as a marker for breast cancer
WO2002063048A3 (en) Methods for predicting sensitivity of tumors to arginine deprivation
EP1636587A4 (de) Einen für menschliches protoonkogenes protein spezifischen antikörper enthaltender diagnostischer kit für leberzirrhose
ATE357662T1 (de) Verfahren der pibf-konzentrationsbestimmung zur diagnose eines tumors in einem patienten
HK1046439A1 (en) Assay

Legal Events

Date Code Title Description
8364 No opposition during term of opposition